UNLABELLED: Hyperammonemia is a feature of acute liver failure (ALF), which is associated with increased intracranial pressure (ICP) and brain herniation. We hypothesized that a combination of L-ornithine and phenylacetate (OP) would synergistically reduce toxic levels of ammonia by (1) L-ornithine increasing glutamine production (ammonia removal) through muscle glutamine synthetase and (2) phenylacetate conjugating with the ornithine-derived glutamine to form phenylacetylglutamine, which is excreted into the urine. The aims of this study were to determine the effect of OP on arterial and extracellular brain ammonia concentrations as well as ICP in pigs with ALF (induced by liver devascularization). ALF pigs were treated with OP (L-ornithine 0.07 g/kg/hour intravenously; phenylbutyrate, prodrug for phenylacetate; 0.05 g/kg/hour intraduodenally) for 8 hours following ALF induction. ICP was monitored throughout, and arterial and extracellular brain ammonia were measured along with phenylacetylglutamine in the urine. Compared with ALF + saline pigs, treatment with OP significantly attenuated concentrations of arterial ammonia (589.6 +/- 56.7 versus 365.2 +/- 60.4 mumol/L [mean +/- SEM], P= 0.002) and extracellular brain ammonia (P= 0.01). The ALF-induced increase in ICP was prevented in ALF + OP-treated pigs (18.3 +/- 1.3 mmHg in ALF + saline versus 10.3 +/- 1.1 mmHg in ALF + OP-treated pigs;P= 0.001). The value of ICP significantly correlated with the concentration of extracellular brain ammonia (r(2) = 0.36,P< 0.001). Urine phenylacetylglutamine levels increased to 4.9 +/- 0.6 micromol/L in ALF + OP-treated pigs versus 0.5 +/- 0.04 micromol/L in ALF + saline-treated pigs (P< 0.001). CONCLUSION: L-Ornithine and phenylacetate act synergistically to successfully attenuate increases in arterial ammonia, which is accompanied by a significant decrease in extracellular brain ammonia and prevention of intracranial hypertension in pigs with ALF.
UNLABELLED: Hyperammonemia is a feature of acute liver failure (ALF), which is associated with increased intracranial pressure (ICP) and brain herniation. We hypothesized that a combination of L-ornithine and phenylacetate (OP) would synergistically reduce toxic levels of ammonia by (1) L-ornithine increasing glutamine production (ammonia removal) through muscle glutamine synthetase and (2) phenylacetate conjugating with the ornithine-derived glutamine to form phenylacetylglutamine, which is excreted into the urine. The aims of this study were to determine the effect of OP on arterial and extracellular brain ammonia concentrations as well as ICP in pigs with ALF (induced by liver devascularization). ALFpigs were treated with OP (L-ornithine 0.07 g/kg/hour intravenously; phenylbutyrate, prodrug for phenylacetate; 0.05 g/kg/hour intraduodenally) for 8 hours following ALF induction. ICP was monitored throughout, and arterial and extracellular brain ammonia were measured along with phenylacetylglutamine in the urine. Compared with ALF + salinepigs, treatment with OP significantly attenuated concentrations of arterial ammonia (589.6 +/- 56.7 versus 365.2 +/- 60.4 mumol/L [mean +/- SEM], P= 0.002) and extracellular brain ammonia (P= 0.01). The ALF-induced increase in ICP was prevented in ALF + OP-treated pigs (18.3 +/- 1.3 mmHg in ALF + saline versus 10.3 +/- 1.1 mmHg in ALF + OP-treated pigs;P= 0.001). The value of ICP significantly correlated with the concentration of extracellular brain ammonia (r(2) = 0.36,P< 0.001). Urine phenylacetylglutamine levels increased to 4.9 +/- 0.6 micromol/L in ALF + OP-treated pigs versus 0.5 +/- 0.04 micromol/L in ALF + saline-treated pigs (P< 0.001). CONCLUSION:L-Ornithine and phenylacetate act synergistically to successfully attenuate increases in arterial ammonia, which is accompanied by a significant decrease in extracellular brain ammonia and prevention of intracranial hypertension in pigs with ALF.
Authors: R Todd Stravitz; Michelle Gottfried; Valerie Durkalski; Robert J Fontana; A James Hanje; David Koch; Bilal Hameed; Daniel Ganger; Ram M Subramanian; Stan Bukofzer; William R Ravis; Kristen Clasen; Averell Sherker; Lanna Little; William M Lee Journal: Hepatology Date: 2018-01-30 Impact factor: 17.425
Authors: Omar Cauli; Alba González-Usano; Andrea Cabrera-Pastor; Carla Gimenez-Garzó; Pilar López-Larrubia; Amparo Ruiz-Sauri; Vicente Hernández-Rabaza; Malgorzata Duszczyk; Michal Malek; Jerzy W Lazarewicz; Arturo Carratalá; Amparo Urios; Alfonso Miguel; Isidro Torregrosa; Carmen Carda; Carmina Montoliu; Vicente Felipo Journal: Neuromolecular Med Date: 2013-12-13 Impact factor: 3.843
Authors: Konstantinos John Dabos; John Andrew Parkinson; Ian Howard Sadler; John Nicholas Plevris; Peter Clive Hayes Journal: World J Hepatol Date: 2015-06-28
Authors: Yue Yu; Hongling Liu; Yasuhiro Ikeda; Bruce P Amiot; Piero Rinaldo; Stephen A Duncan; Scott L Nyberg Journal: Stem Cell Res Date: 2012-06-28 Impact factor: 2.020
Authors: Jasmohan S Bajaj; Vishwadeep Ahluwalia; James B Wade; Arun J Sanyal; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Richard K Sterling; Velimir Luketic; Iliana Bouneva; Richard T Stravitz; Puneet Puri; Kenneth A Kraft; Hochong Gilles; Douglas M Heuman Journal: J Hepatol Date: 2012-08-11 Impact factor: 25.083
Authors: Ji Bao; James E Fisher; Joseph B Lillegard; William Wang; Bruce Amiot; Yue Yu; Allan B Dietz; Yaakov Nahmias; Scott L Nyberg Journal: Cell Transplant Date: 2012-09-21 Impact factor: 4.064